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Background: Microglia play key roles in innate immunity, homeostasis, and neurotropic support in the central
nervous system. Similar to macrophages, microglia adopt two different activation phenotypes, the classical and
alternative activation. Resolvin D1 (RvD1) is considered to display potent anti-inflammatory and pro-resolving
actions in inflammatory models. In this present study, we investigate the effect of RvD1 on IL-4-induced alternative
activation in murine BV-2 microglial cells.
Methods: BV-2 cells were incubated with RvD1 alone, IL-4 alone, or the combination of RvD1 and IL-4. Western blot
and immunofluorescence were performed to detect protein levels of alternative activation markers arginase 1
(Arg1), chitinase 3-like 3 (Ym1). Moreover, we investigated the effects of RvD1 on IL-4-induced activation of signal
transducer and activators of transcription 6 (STAT6) and peroxisome proliferator-activated receptor gamma (PPARγ).
Results: RvD1 promoted IL-4-induced microglia alternative activation by increasing the expression of Arg1 and
Ym1. RvD1 also enhanced phosphorylation of STAT6, nuclear translocation of PPARγ and the DNA binding activity
of STAT6 and PPARγ. These effects were reversed by butyloxycarbonyl-Phe-Leu-Phe-Leu-Phe (a formyl peptide
receptor 2 antagonist). Further, the effects of RvD1 and IL-4 on Arg1 and Ym1 were blocked by the application of
leflunomide (a STAT6 inhibitor) or GW9662 (a PPARγ antagonist).
Conclusions: Our studies demonstrate that RvD1 promotes IL-4-induced alternative activation via STAT6 and
PPARγ signaling pathways in microglia. These findings suggest that RvD1 may have therapeutic potential for
neuroinflammatory diseases.
Keyword: Resolvin D1, Microglia, Alternative activation, STAT6, PPARγBackground
Microglia are considered to be the resident immune cells of
the central nervous system (CNS). In the normal CNS,
microglia survey their surrounding microenvironment [1].
However, in a pathological state, microglia respond to en-
vironmental changes with a variety of activation states,
changing both morphology and phenotype [2].
It is becoming increasingly clear that microglia, like mac-
rophages, have at least two polarized activation states:* Correspondence: you_shang@yahoo.com
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unless otherwise stated.classical and alternative activation [3-6]. Classical activation
(M1) induced by lipopolysaccharide (LPS) or Th1 cytokines
is associated with elevations of pro-inflammation cytokines
such as IL-1, IL-6 and TNF-α, nitric oxide (NO) and react-
ive oxygen species (ROS), which are involved in pathogen
destruction and cytotoxicity [7,8]. Alternative activation
(M2) induced by Th2 cytokines IL-4, IL-13 or IL-10 is asso-
ciated with elevation of arginase 1 (Arg1), chitinase 3-like 3
(Ym1), mannose receptor and found in inflammatory zone
1 (FIZZ1), which is primarily involved in tissue remodeling
and healing [7,8]. Therefore, modulating microglia activa-
tion states may be a potential therapeutic targeting of neu-
roinflammatory diseases.
Signal transducer and activators of transcription 6
(STAT6) is activated by IL-4 and IL-13 and plays an im-
portant role in alternative activation. STAT6 is able tohis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Li et al. Journal of Neuroinflammation 2014, 11:72 Page 2 of 11
http://www.jneuroinflammation.com/content/11/1/72regulate transcription of genes typical of M2 activation
[9,10]. Downstream of STAT6, peroxisome proliferator-
activated receptor gamma (PPARγ) is activated in a
STAT6-dependent manner [11]. PPARγ is a member of the
nuclear hormone receptor superfamily and is considered to
associate with lipid metabolism, oxidative metabolism,
macrophage and microglia M2 polarization [12-14].
Resolvins are a family of bioactive metabolites de-
rived from omega-3 fatty acids docosahexaenoic acid
(DHA) and eicosapentaenoic acid (EPA) and display
potent anti-inflammatory and pro-resolving actions in
inflammatory models [15]. Resolvin D1 (7S,8R,17S-tri-
hydroxy-4Z,9E,11E,13Z,15E,19Z-DHA, RvD1) is pro-
duced physiologically from the sequential oxygenation
of DHA by 15-lipoxygenase and 5-lipoxygenase [16].
RvD1 directly activates lipoxin A4 receptor/formyl peptide
receptor 2 (ALX/FPR2) and orphan receptor G protein
coupling receptor 32 (GPR32), limits excessive leukocyte
infiltration, attenuates the production of pro-inflammatory
cytokines [17], regulates macrophage phagocytosis [18] and
up-regulates pro-resolving miRNAs [19]. RvD1 can also eli-
cite macrophage polarization toward an M2-like phenotype
[20]. Previous research has indicated that another ALX/
FPR2 activator, aspirin-triggered lipoxin A4, can down-
regulate the LPS-induced expression of M1 markers
in microglia [21-23]. However, the effect of RvD1 on micro-
glia M2 polarization and molecular mechanisms is still
unknown.
Here, we investigated the impact of RvD1 on IL-4-
induced expression of M2 markers in BV-2 microglial
cells and the signaling pathways involving in these pro-
cesses. Our data show that RvD1 up-regulates expression
of Arg1 and Ym1 in IL-4-treated microglial cells de-
pending on STAT6 and PPARγ signaling pathways.
Methods
Cell culture
The immortalized murine microglia cell line BV-2 was
purchased from the Cell Resource Center of Peking
Union Medical College (Beijing, China) and maintained
in DMEM with F12 supplement (DMEM/F12, Gibco,
Grand Island, NY, USA) supplemented with 10% FBS
(Gibco, Grand Island, NY, USA), 100 U/ml penicillin
and 100 μg/ml streptomycin at 37°C in a humidified at-
mosphere of 95% air and 5% CO2. Before each experi-
ment, cells were serum-starved for 12 hours. BV-2 cells
were incubated with different concentrations (1 nM, 10
nM or 100 nM) of RvD1 (Cayman Chemical, Ann Arbor,
MI, USA) or vehicle (0.038% ethanol) for 30 minutes be-
fore addition of 10 ng/ml murine IL-4 (PeproTech,
Hamburg, Germany) under serum-free conditions. To
investigate the involvement of ALX, STAT6 or PPARγ,
the cells were treated with 10 μM butyloxycarbonyl-
Phe-Leu-Phe-Leu-Phe (Boc-2) (GenScript Corporation,Piscataway, NJ, USA), 100 μM leflunomide (Sigma-
Aldrich, St. Louis, MO, USA) or 1 μM GW9662 (Sigma-
Aldrich, St. Louis, MO, USA) prior to the treatment
with RvD1 for 30 minutes.
Immunocytochemistry
BV-2 cells were cultured on sterile glass cover slips and
treated according to the experimental design. Afterward,
cells were fixed with 4% paraformaldehyde in PBS and
permeabilized with 0.1% Triton X-100 in PBS. After
rinsing, cells were blocked with 3% BSA in PBS for one
hour and incubated with primary antibodies overnight at
4°C. The primary antibodies used were as follows:
rabbit anti-arginase-1 (1:100, Santa Cruz, Heidelberg,
Germany), Ym1 (1:50, Stem Cell Technologies, Vancouver,
Canada), PPARγ (1:100, Santa Cruz, Heidelberg, Germany).
After washing, cells were incubated with FITC-conjugated
goat anti-rabbit IgG (1:400, Jackson Immuno Research
Laboratories, West Grove, PA, USA) for one hour
and counterstained with 4, 6-diamidino-2-phenylindole
(DAPI, Roche, Shanghai, China) for the identification
of nuclei. After washing with PBS, the cover slips were
mounted with antifade mounting medium (Beyotime,
Shanghai, China) on slides, and the cells were observed
with an Olympus immunofluorescence microscope
(Olympus, Tokyo, Japan).
Protein extraction
For making whole cell lysates, the cells were lysed in radio-
immune precipitation assay (RIPA) buffer supplemented
with protease inhibitor cocktail (Roche, Shanghai, China).
Nuclear and cytoplasmic fractionations were performed
with NE-PER Nuclear and Cytoplasmic Extraction Re-
agents (Thermo Scientific, Rockford, IL, USA) according to
manufacturer’s protocol.
Western blot analysis
Equal amounts of nuclear or whole cell extracts were elec-
trophoresed on sodium dodecyl sulfate-polyacrylamide gels,
and then transferred onto a polyvinylidene difluoride mem-
brane (Millipore, Schwalbach, Germany). The transformed
membrane was blocked with 5% non-fat dry milk in Tris-
buffered saline containing 0.05% Tween-20 (TBST) for one
hour and incubated with primary antibodies overnight at
4°C. The primary antibodies used were as follows: rabbit
anti-arginase-1 (1:500), Ym1 (1:1,000), PPARγ (1:500),
phospho-Stat6 (1:500, Santa Cruz, Heidelberg, Germany),
β-actin (1:1,000, Santa Cruz, Heidelberg, Germany), lamin
B1 (1:1,000, Santa Cruz, Heidelberg, Germany). The mem-
brane was washed three times with TBST for ten minutes
and incubated with anti-rabbit IgG-horseradish peroxidase
(1:5,000, Jackson ImmunoResearch Laboratories, West
Grove, PA, USA) at room temperature for one hour. The
Supersignal West Pico chemiluminescent substrate system
Figure 1 (See legend on next page.)
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Figure 1 RvD1 promotes the IL-4-induced alternative activation of BV-2 cells. BV-2 cells were treated with vehicle (0.038% ethanol) or
different concentrations of RvD1 (1 nM, 10 nM and 100 nM) for 30 minutes in the absence or presence of Boc-2 (10 μM), and then stimulated by
IL-4 (10 ng/ml) for 24 hours. (A, B) The expression of Arg1 and Ym1 proteins was assessed by Western blot. A representative result from three
independent experiments is shown. Quantification for Arg1 and Ym1 was normalized by β-actin. Data are presented as mean ± SEM for three
independent experiments. Asterisks indicate statistically significant difference (*P < 0.05, **P < 0.01). (C, D) Representative images of BV-2 cells with
positive immunofluorescence staining for Arg1 (C) and Ym1 (D). Scale bars indicate 20 μm.
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munoreactive bands. The intensity of protein bands after
Western blot were quantitated by using Quantity One Ver-
sion 4.6.3 Image software (Bio-Rad, Hercules, CA, USA)
and normalized against proper loading controls.Electrophoretic mobility shift assay (EMSA)
Nuclear extracts were prepared as described above. Oligo-
nucleotides corresponding to the STAT6 (5′-TGCCT
TAGTCAACTTCCCAAGAACAGA-3′) and PPARγ (5′-
GGAACTAGGTCAAAGGTCATCCCCT-3′) binding site
consensus sequences were synthesized and end-labeled
with biotin by Invitrogen (Invitrogen, Shanghai, China).
EMSAs were performed using the LightShift chemilumin-
escent EMSA kit (Thermo Scientific, Rockford, IL, USA).
Briefly, 10 fmol of biotin-labeled, double strand probe
were incubated for 20 minutes at room temperature in 20
μl of EMSA binding buffer containing 2.5% glycerol, 5
mM MgCl2, 50 ng/μl poly (dI-dC), 0.05% Nonidet P-40,
and 6 μg of nuclear proteins. For competition EMSA,
200-fold (2 pmol) excess unlabeled, double strand probe
was added to the binding reaction. The DNA-nuclear pro-
tein complexes were resolved by electrophoresis in 6%
nondenaturing polyacrylamide gel in 0.5 × Tris-borate-
EDTA (TBE) buffer at 100 V. Gels were then electro-
blotted onto Hybond nylon membranes (GE Healthcare,
Freiburg, Germany) at 380 mA for 50 minutes. The mem-
branes were then cross-linked for 15 minutes with the
membrane face down on a transilluminator at 312 nm,
and the biotinylated protein-DNA bands were detected
with HRP-conjugated streptavidin using the chemilumin-
escent nucleic acid detection system.Statistical analysis
Data are expressed as means ± SEM of the indicated
number of independent experiments. Statistical sig-
nificance between multiple groups was analyzed by
one-way ANOVA. Least significant difference (LSD)
post hoc test was used for multiple comparisons. Stat-
istical analysis was performed using the SPSS software
version 13.0 (SPSS Inc., Chicago, IL, USA). P < 0.05
was considered statistically significant.Results
RvD1 promotes IL-4-induced alternative activation of
BV-2 microglial cells
Initially, we evaluated the effects of RvD1 on IL-4-
induced microglia alternative activation; BV-2 cells were
treated with vehicle or different concentrations of RvD1
(1 nM, 10 nM and 100 nM) for 30 minutes and stimu-
lated with IL-4 (10 ng/ml) for 24 hours. As the assess-
ment of the alternative activation relied on the molecule
markers such as Arg1 and Ym1, the expression of Arg1
and Ym1 were analyzed. We tested the protein levels of
Arg1 and Ym1 using Western blot analysis. As shown in
Figure 1A, IL-4 stimulation significantly enhanced Arg1
and Ym1 protein levels in BV-2 cells (P <0.01). Treat-
ment with RvD1 alone did not affect Arg1 and Ym1
protein levels (P > 0.05); while combination of RvD1 and
IL-4 markedly increased expression of Arg1 and Ym1 in
BV-2 cells compared to IL-4 treatment alone, the effects
of RvD1 were concentration dependent. Immunofluores-
cence staining demonstrated that Arg1 and Ym1 staining
intensity increased after IL-4 treatment, pretreatment
with RvD1 further increased the staining intensity
(Figure 1C and D).
To evaluate the role of ALX/FPR2 in the effects of
RvD1, an ALX antagonist Boc-2 (10 μM) was admin-
istrated 30 minutes prior to treatment with RvD1.
The effects in response to RvD1 were reversed by
Boc-2 (Figure 1B-D).RvD1 promotes IL-4-induced STAT6 phosphorylation and
activation
STAT6 plays a critical role in IL-4-dependent induction
of Arg1 and Ym1 [24,25]. As RvD1 promotes IL-4-
induced expression of Arg1 and Ym1 (Figure 1), we in-
vestigated the involvement of STAT6 activation in these
effects. STAT6 phosphorylated at 60 minutes after IL-4
treated (Figure 2A), the 60 minute treatment of IL-4 was
determined to examine the effect of RvD1 on STAT6
phosphorylation. RvD1 markedly enhanced IL-4-induced
phosphorylation of STAT6 (P < 0.01), the effect of RvD1
was reversed by Boc-2 (P <0.05, Figure 2B). Further, we
performed EMSA to determine the effects RvD1 and IL-
4 on STAT6 DNA binding activity in BV-2 cells. IL-4
Figure 2 RvD1 enhances IL-4-induced STAT6 activation. (A) BV-2 cells were treated with IL-4 (10 ng/ml) for the indicated times, expression of
phosphorylated STAT6 was assessed by Western blot. Quantification of phospo-STAT6 from three independent experiments indicated that the
effect of IL-4 was obvious at 60 minutes. (B) BV-2 cells were treated with RvD1 (100 nM), IL-4 (10 ng/ml), Boc-2 (10 μM) or combination of them.
Levels of phosphorylated STAT6 were detected by Western blot 60 minutes after IL-4 stimulation. A representative result from three independent
experiments is shown. Quantification of phosphorylated STAT6 was normalized by β-actin. (C) BV-2 cells were treated as in (B). Nuclear extracts
were prepared 120 minutes after IL-4 treatment and used to analyze STAT6 DNA binding activity by Electrophoretic Mobility Shift Assay (EMSA).
Binding specificity was confirmed by unlabelled probe (200-fold in excess) to compete with labeled oligonucleotide. Results were confirmed by
three independent experiments. Data are presented as mean ± SEM for three independent experiments. Asterisks indicate statistically significant
difference (*P < 0.05, **P < 0.01).
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ation of RvD1 and IL-4 further increased the activity.
Moreover, treatment with Boc-2 reversed the effect of
RvD1 (Figure 2C).RvD1 promotes IL-4-induced PPARγ nuclear translocation
and activation
Along with STAT6, PPARγ is known to control genes asso-
ciated with alternatively activation [12,26]. Therefore, we
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nuclear translocation and DNA binding activity in BV-2
cells. Immunofluorescence staining indicated that PPARγ
translocated from the cytoplasm into the nucleus obviously
120 minutes after IL-4 stimulation (Figure 3A). Then we
tested whether IL-4 and RvD1 affected PPARγ proteinFigure 3 RvD1 enhances IL-4-induced PPARγ activation. (A) BV-2 cells
localization of PPARγ was evaluated using immunofluorescence staining. D
nuclei. The nuclear translocation of PPARγ was obvious 120 minutes after s
with RvD1 (100 nM), IL-4 (10 ng/ml), Boc-2 (10 μM) or a combination of the
Western blot or electrophoretic mobility shift assay (EMSA) were performed
(C). A representative result from three independent experiments is shown.
presented as mean ± SEM for three independent experiments. Asterisks indlevels in nucleus and DNA binding activity. As shown in
Figure 3B and C, IL-4 increased PPARγ protein levels in
nucleus and DNA binding activity. RvD1 alone failed to ac-
tivate PPARγ (P > 0.05). However, combination of RvD1
and IL-4 further increased PPARγ protein levels in nucleus
and DNA binding activity compared to treatment with IL-4were treated with IL-4 (10 ng/ml) for the indicated times, subcellular
NA was stained using 6-diamidino-2-phenylindole (DAPI) to visualize
timulation. Scale bars indicate 20 μm. (B, C) BV-2 cells were treated
m. Nuclear extracts were prepared 120 minutes after IL-4 treatment,
to detect PPARγ protein level in nucleus (B) or DNA binding activity
Quantification of PPARγ was normalized by lamin B1. Data are
icate statistically significant difference (*P < 0.05, **P < 0.01).
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with Boc-2.
STAT6 is required for PPARγ activation induced by IL-4
and RvD1
STAT6 is a regulator of PPARγ response; IL-4 induces
augmented PPARγ activity through a STAT6-dependent
mechanism [11,27]. To identify the role of STAT6 on
PPARγ activation induced by IL-4 and RvD1, we used
leflunomide (an inhibitor suppressing tyrosine phosphor-
ylation of STAT6 and preventing subsequent DNA bind-
ing) and GW9662 (a PPARγ antagonist) [26,28]. One
hundred micromoles of leflunomide or 1 μM GW9662
was administrated 30 minutes prior to treatment with
RvD1, PPARγ expression and DNA binding activity were
analyzed. Consistent with GW9662, leflunomide de-
creased PPARγ protein levels in nucleus and DNA bind-
ing activity in IL-4 and RvD1 treated BV-2 cells
(Figure 4).
STAT6 and PPARγ are essential for induction of Arg1 and
Ym1 by IL-4 and RvD1
RvD1 promotes IL-4-induced STAT6 and PPARγ acti-
vation, these facts suggest, but do not prove, thatFigure 4 STAT6 is required for PPARγ activation. BV-2 cells were treated wi
administration of RvD1 (100 nM), followed by incubation with IL-4 (10 ng/ml) fo
(B) were analyzed using Western blot or electrophoretic mobility shift assay (EM
Quantification of PPARγ was normalized by lamin B1. Data are presented as me
significant difference (*P< 0.05, **P< 0.01).STAT6 and PPARγ are required for the effects of
RvD1 and IL-4 on Arg1 and Ym1 induction. To dir-
ectly test the effects of STAT6 and PPARγ, BV-2 cells
were pretreated with 100 μM leflunomide or 1 μM
GW9662 for 30 minutes to inhibit STAT6 or PPARγ
signaling pathway and stimulated with RvD1 and IL-4
for 24 hours. Immunofluorescence and Western blot
were performed to determine Arg1 and Ym1 expres-
sion. As expected, Arg1 and Ym1 induction by RvD1
and Ym1 was markedly blunted by inhibition of
STAT6 and PPARγ (Figure 5).
Discussion
In this study, we provide the first evidence that RvD1
enhances the IL-4-induced M2 polarization in BV-2
microglial cells. Pretreatment with RvD1 was able to in-
crease IL-4-induced expression of two major alternative
activation markers, Arg1 and Ym1. In addition, RvD1
potentiated the effects of IL-4 on STAT6 and PPARγ sig-
naling pathways, administering leflunomide or GW9662
before RvD1 and IL-4 blunted the induction of Arg1 and
Ym1. These results suggest that RvD1 can promote IL-
4-induced M2 polarization in microglial cells via STAT6
and PPARγ signaling pathways.th leflunomide (10 μM) or GW9662 (1 μM) 30 minutes prior to
r 120 minutes. PPARγ protein level in nucleus (A) and DNA binding activity
SA). A representative result from three independent experiments is shown.
an ± SEM for three independent experiments. Asterisks indicate statistically
Figure 5 Inhibition of STAT6 and PPARγ impacts microglia alternative activation induced by IL-4 and RvD1. BV-2 cells were treated with
leflunomide (10 μM) or GW9662 (1 μM) 30 minutes prior to administration of RvD1 (100 nM) and then stimulated with IL-4 (10 ng/ml) for 24
hours. Immunofluorescence assay for Arg1 (A) and Ym1 (B) indicated that the induction of Arg1 and Ym1 by RvD1 and IL-4 was disappeared
when blocking STAT6 or PPARγ signaling pathway. Scale bars indicate 20 μm. (C) The protein levels of Arg1 and Ym1 were measured by Western
blot. A representative result from three independent experiments is shown. Quantification for Arg1 and Ym1 was normalized by β-actin. Data are
presented as mean ± SEM for three independent experiments. Asterisks indicate statistically significant difference (*P < 0.05, **P < 0.01).
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ALX/FPR2 and an orphan, GPR32. RvD1 activates ALX
and GPR32 with high affinity (EC50 approximately 1.2
pM for ALX/FPR2 and 8.8 pM for GPR32) [18]. Interest-
ingly, on human polymorphonuclear leukocytes, lowconcentration of RvD1 (1 nM) appear sensitive to
GPR32 blockade, while responses to high concentration
(10 nM) are ALX-dependent [29]. Our findings demon-
strated that RvD1 promoted IL-4-induced microglia al-
ternative activation with high concentrations (10 nM
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not identify the murine orthologs of human GPR32,
while mouse ALX has been confirmed to express in
neuron, astrocyte, microglia, neutrophils, macrophage
and monocyte, as well as BV-2 cells [21,30]. Boc-2 is an
ALX/FPR2 antagonist, and can block the ability of RvD1
[31]. Thus, we investigated the receptor dependency of
RvD1 in microglia M2 polarization by using Boc-2. Pre-
vious studies have shown that activation of ALX by
lipoxin A4, RvD1, BML-111 or other agonists have po-
tential anti-inflammatory and pro-resolving effects in a
rat brain ischemia-reperfusion injury model [32,33] and
other inflammatory disease models [34-37]. These find-
ings suggest that RvD1 could modulate the inflammatory
reaction in CNS diseases.
Microglia exhibit various functions at different stages
in life or in response to different pathological situations
[6]. The activation states of microglia are plastic and
flexible, both blunting classical activation and promoting
alternative activation are involving in anti-inflammatory
and pro-resolving process. Here, we used Arg1 and Ym1
as markers for microglia alternative activation. Expres-
sion of Arg1 in microglia is induced by Th2 cytokines
[38]. Arg1 can reduce NO production, and it is also in-
volved in wound healing, fibrosis and supporting neuronFigure 6 Schematic representation of the RvD1 contribution to micro
alternative activation by increasing Arg1 and Ym1 expression via STAT6/PPsurvival [39-41]. Apart from Arg1, Ym1 is another
marker for alternative activation [42]. Ym1 is considered
to be associated with tissue remodeling and regulating
inflammation [43]. First, we examined the effect of IL-4
and RvD1 on Arg1 and Ym1 expression. According with
previous studies, our results showed that expression of
Arg1 and Ym1 was low in unstimulated BV-2 microglial
cells, which was enhanced by stimulation with 10ng/ml
IL-4 [7,44]. Titos et al. reported that RvD1 and its
precursor DHA promoted resolution by eliciting macro-
phage M2 polarization [20]. In our study, treatment
with RvD1 alone had no effect on Arg1 and Ym1
expression in microglia, while pretreatment with RvD1
enhanced the effect of IL-4 on Arg1 and Ym1 expres-
sion. This indicated that RvD1 may be possible to
promote resolution of neuroinflammation by regulating
microglia polarization. The effect of RvD1 was receptor-
dependent as it was reversed by the use of ALX antagonist
Boc-2.
The synergistic effect of RvD1 and IL-4 on Arg1 and
Ym1 expression might be explained by RvD1 potentiating
IL-4-induced STAT6 and PPARγ activation. IL-4-induced
expression of Arg1 and Ym1 depends on activation of
STAT6. In response to IL-4, STAT6 is phosphorylated,
translates into the nucleus and binds to consensus sites atglia alternative activation. RvD1 promotes IL-4-induced microglia
ARγ signaling pathway.
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tion of M2 marker genes [45]. STAT6 can also modulate
the activity of nuclear receptor PPARγ [11]. PPARγ plays
an important role in macrophage/microglia alternative acti-
vation; the addition of a PPARγ agonist directly regulates
the Arg1 and Ym1 expression [12,14,46,47]. In this study,
RvD1 was able to enhance the phosphorylation and DNA
binding activity of STAT6 induced by IL-4. Inhibiting
STAT6 by leflunomide abolished the induction of Arg1 and
Ym1. Moreover, leflunomide inhibited PPARγ translocating
into the nucleus and binding to DNA sites, which sug-
gested that STAT6 was required for PPARγ activation in-
duced by RvD1 and IL-4. Consistent with STAT6, the
activity of PPARγ induced by RvD1 and IL-4 was greater
than stimulating with IL-4 alone. A previous study reported
that activation of PPARγ by pioglitazone promoted micro-
glia M2 polarization by increasing Arg1 and Ym1 expres-
sion [14]. In our research, the effects of RvD1 and IL-4 on
Arg1 and Ym1 were impaired by using PPARγ antagonist
GW9662, which proved PPARγ was essential for RvD1 and
IL-4-induced microglia alternative activation. These find-
ings suggested that RvD1 enhanced IL-4-induced microglia
alternative activation depending on the STAT6/PPARγ sig-
naling pathway (Figure 6).Conclusions
Our results show that RvD1 promotes IL-4-induced micro-
glia alternative activation. A possible mechanism relates to
activation of STAT6 and PPARγ signaling pathways. Given
the anti-inflammatory and pro-resolving effects of RvD1, it
may be a potential treatment for CNS diseases involving
neuroinflammation.Abbreviations
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